Novel Targetable BIOmarkers in ANorexia NervosA - BIOANNA

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The overall aim of this present study is to evaluate Growth Differentiation Factor-15 (GDF-15) and inflammatory cytokines as a possible novel and readily treatable target for the successful therapy of Anorexia Nervosa (AN). Therefore, GDF-15, neuronal and glial damage markers such as Neurofilament light chain (Nfl) and Glial fibrillary acidic protein (GFAP) and cytokines (such as Tumor necrosis factor alpha (TNF-α), Interleukin-6 (IL-6), and Interleukin 1β (IL-1β) levels will be assessed in the serum as well as in the cerebrospinal fluid of patients with diagnosed restrictive AN with and without exercising behavior compared to sex- and age-matched healthy controls to consolidate previous findings and to identify the main site of production of GDF-15 and cytokines in AN.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 60
Healthy Volunteers: t
View:

• Age 18-60 years

• Written informed consent

• BMI 10-16 kg/m2

⁃ N=8 adult male and female patients with confirmed diagnosis of anorexia nervosa restrictive type, exercising subtype will be included in this study.

• Age 18-60 years

• Written informed consent

• BMI 10-16 kg/m2

⁃ N=16 control participants, sex- and age-matched to the individual anorexia nervosa patients.

• Age 18-60 years

• Written informed consent

• BMI 19-24.9 kg/m2

Locations
Other Locations
Switzerland
University Hospital Basel
RECRUITING
Basel
Contact Information
Primary
Katharina Timper, Prof.
katharina.timper@usb.ch
+41613285742
Backup
Valerie Mettraux
valerie.mettraux@usb.ch
+41613285520
Time Frame
Start Date: 2023-05-01
Estimated Completion Date: 2025-04-30
Participants
Target number of participants: 32
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Basel, Switzerland
Collaborators: University of Zurich

This content was sourced from clinicaltrials.gov